IView Therapeutics was awarded SBIR Innovative Year 2 Grant by NIH’s National Institute of Allergy and Infectious Diseases (NIAID)

By WebmasterApril 11, 2019November 1st, 2024No Comments

IView Therapeutics was awarded SBIR Innovative Year 2 Grant by NIH’s National Institute of Allergy and Infectious Diseases (NIAID)

Previous PostPalvella Therapeutics raises $3M to advance rare disease drug
Next PostVenatoRx Pharmaceuticals Names Lisa Wittmer, Ph.D. Chief Development Officer